Global Post-Translational Modification Profiling of HIV-1-Infected Cells Reveals
Total Page:16
File Type:pdf, Size:1020Kb
bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling Jeffrey R. Johnson1,2,3,4*, David C. Crosby5, Judd F. Hultquist1,2,3,6, Donna Li7, John Marlett8, Justine Swann8, Ruth Hüttenhain1,2,3, Erik Verschueren9, Tasha L. Johnson1,2,3, Billy W. Newton1,2,3, Michael Shales1,2,3, Pedro Beltrao10, Alan D. Frankel2, Alexander Marson11,12,13,14, Oliver I. Fregoso15, John A. T. Young16, Nevan J. Krogan6,7,8,* 1Department of Cellular and Molecular Pharmacology; University of California San Francisco; San Francisco, CA, 94158; USA 2Quantitative Biosciences Institute; University of California San Francisco; San Francisco, CA, 94158; USA 3Gladstone Institute for Data Science and Biotechnology; Gladstone Institutes; San Francisco, CA, 94158; USA 4Present address: Department of Microbiology; Icahn School of Medicine at Mount Sinai; New York, NY, 10029; USA 5Department of Biochemistry; University of California San Francisco; San Francisco, CA, 94158; USA 6Present address: Division of Infectious Diseases; Northwestern University Feinberg School of Medicine; Chicago, IL, 60611; USA 7Cancer Biology Graduate Program; University of Wisconsin School of Medicine and Public Health; Madison, WI, 53726; USA 8Viral Vector Core; Salk Institute for Biological Studies; La Jolla, CA, 92037; USA 9Proteomics and Biological Resources; Genentech, Inc.; South San Francisco, CA, 94080; USA bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 10European Molecular Biology Laboratory, European Bioinformatics Institute; Wellcome Genome Campus; Hinxton, Cambridge, CD10 1SD; UK 11Department of Microbiology and Immunology; University of California San Francisco; San Francisco, CA, 94143; USA 12Diabetes Center; University of California San Francisco; San Francisco, CA, 94143; USA 13Innovative Genomics Institute; University of California Berkeley; Berkeley, CA, 94720; USA 14Department of Medicine; University of California San Francisco; San Francisco, CA, 94143l USA 15Deparment of Microbiology, Immunology, and Molecular Genetics; University of California Los Angeles; Los Angeles, CA, 90095; USA 16Roche Pharma Research and Early Development; Roche Innovation Center Basel; 4070 Basel; Switzerland *Correspondence: [email protected]; [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SUMMARY Viruses must effectively remodel host cellular pathways to replicate and evade immune defenses, and they must do so with limited genomic coding capacity. Targeting post- translational modification (PTM) pathways provides a mechanism by which viruses can broadly and rapidly transform a hostile host environment into a hospitable one. We used quantitative proteomics to measure changes in two PTM types – phosphorylation and ubiquitination – in response to HIV-1 infection with viruses harboring targeted deletions of a subset of HIV-1 genes. PTM analysis revealed a requirement for Aurora kinase A activity in HIV-1 infection and furthermore revealed that AMP-activated kinase activity is modulated during infection via HIV-1 Vif-mediated degradation of B56-containing protein phosphatase 2A (PP2A). Finally, we demonstrated that the Cullin4A-DDB1-DCAF1 E3 ubiquitin ligase ubiquitinates histone H1 somatic variants and that HIV-1 Vpr inhibits this process, leading to defects in DNA repair. Thus, global PTM profiling of infected cells serves as an effective tool for uncovering specific mechanisms of host pathway modulation. KEYWORDS HIV-1, proteomics, phosphorylation, ubiquitination, systems biology, vpr, histone h1, vif, pp2a, b56, ampk, ampd2 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. INTRODUCTION Human immunodeficiency virus type-1 (HIV-1) remains a major threat to public health worldwide. While there has been tremendous success in the development of combination antiretroviral therapies (cART) for treatment and prophylaxis, there is a need for next-generation therapies that are less toxic, have fewer side effects, and are longer-acting. Drug resistance is also a threat to existing therapies, with an estimated 10 percent of people received cART that are resistant to at least one drug in their cART formulation (Organization, 2017). The identification of new drug targets is critical to next-generation antiretroviral drug development, and as such a precise molecular understanding of HIV-1 gene functions is of critical importance. The HIV-1 genome encodes several accessory genes that are dispensable for replication in some cell lines but are required for evasion of host antiviral pathways and in vivo replication and pathogenesis. Three accessory genes, Vif, Vpr, and Vpu, bind to Cullin RING-type E3 ubiquitin ligases in order to rewire host ubiquitination systems and antagonize antiviral host pathways (Sauter and Kirchhoff, 2018). The HIV-1 Vif protein binds to the Cullin-5/Elogin-B/Elongin-C RING-type E3 ubiquitin ligases (CRL5EloB/EloC) in order to promote ubiquitination and proteasomal degradation of antiviral APOBEC3 proteins, a family of single-stranded DNA-editing enzymes with the capacity to incorporate into HIV-1 virions and inactivate the virus by hypermutation of the genome during reverse transcription (eehy et al., 2002; Harris et al., 2003). Vif also targets the PP2A-B56 subfamily of protein phosphatases for ubiquitination and degradation, and this degradation is associated with G2 cell cycle arrest (Greenwood et al., 2016; Salamango et al., 2019). The substrate(s) of PP2A-B56 affected by its degradation and the molecular mechanism underlying Vif-mediated G2 arrest remains unknown. The HIV-1 Vpu protein binds to the Cullin-1/Skp1/βTrCP ligase (SCFβTrCP) to promote bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ubiquitination and removal from the cell surface of BST/tetherin, an antiviral protein that inhibits viral budding and release (Neil et al., 2008). HIV-2, an independent zoonotic transmission of simian immunodeficiency virus (SIV) from primate in humans that is distinct from HIV-1, encodes the additional Vpx protein that binds to the Cullin4/DDB1/DCAF1 (CRL4DCAF1) ligase to promote ubiquitination and degradation of the antiviral protein SAMHD1, which restricts free deoxynucleotide pools and impairs viral reverse transcription (Hrecka et al., 2011; Laguette et al., 2011). Intriguingly, HIV- 2 Vpx also utilizes CRL4DCAF1 to promote ubiquitination and degradation of the HUSH transcriptional silencing complex that otherwise acts to silence incoming proviruses in the nucleus (Chougui et al., 2018; Dahabieh et al., 2015; Lai and Pugh, 2017; Yurkovetskiy et al., 2018). It is not yet clear whether HUSH is wired to the innate immune system. The HIV-1 Vpr protein also binds to CRL4DCAF1, but it does not share SAMHD1 and HUSH inactivation functions with HIV-2 Vpx. Several Vpr-CRL4DCAF1 substrates have been identified including the uracil N-glycosylase 2 (UNG2), Mus81 (part of the SLX4 complex), helicase-like transcription factor (HLTF), exonuclease 1 (EXO1), and Tet DNA dioxygenase 2 (TET2) (Laguette et al., 2014; Lahouassa et al., 2016; Lv et al., 2018; Yan et al., 2018). However, only TET2 has been demonstrated to rescue a replication defect of Vpr-deficient viral replication in primary monocyte-derived macrophages and the rescue was only partial (Wang and Su, 2019). Furthermore, none of the Vpr-CRL4DCAF1 substrates identified thus far explain the ability of Vpr to potently activate cell cycle arrest at the G2/M-phase checkpoint. The identification of post-translational modification (PTM) enzyme-substrate relationships can be challenging due to the relatively transient nature of their physical interactions. The discoveries of APOBEC3 and BST2/tetherin proteins as ubiquitination targets of Vif-CRL5ELOB/ELOC and Vpu-SCFβTrCP, respectively, were made by comparing bioRxiv preprint doi: https://doi.org/10.1101/2020.01.06.896365; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. gene expression patterns in closely related cell lines that were permissive or non- permissive to HIV-1 replication with Vif- and Vpu-deficient viruses. Conversely, the suite of Vpr and Vpx substrates have been identified by physical interactions with Vpr/Vpx- CRL4DCAF1, as suitable non-permissive cell lines for HIV-1 replication with Vpr- or Vpx- deficient viruses have not been established.